Shayesteh Fürst-Ladani is the CEO and founder of SFL.
She leads the team at SFL and provides global strategic support for the development of healthcare products. Shayesteh is President of the not-for-profit Associations “Rare Disease Action Forum” (RDAF) as well as the “Medtech & Pharma Platform” (MPP).
Shayesteh has longstanding experience in formulating global regulatory strategy for drugs, orphan drugs, drug & device combination products, borderline products, medical devices, in vitro diagnostics (IVDs) and advanced therapy medicinal products (ATMPs).
She has extensive experience in negotiating companies’ interests at a senior level in meetings with regulators. Shayesteh has been involved in reviewing and assessing the impact of many European and US legislation.
She is a Special Coach for Regulatory Affairs at Innosuisse (the Swiss Innovation Agency). Shayesteh is a Lecturer in Regulatory Affairs at the IFAPP Academy, Kings College London and previously spent 7 years as an Adjunct Instructor for Regulatory Affairs at the George Washington University School of Medicines and Health Sciences. She is frequently invited as a speaker and/or chair in international conferences.
Before founding SFL, Shayesteh held senior positions as Head of Global Regulatory Affairs and Head of Regulatory Affairs for Development Products at various biotech and major pharmaceutical companies.
Shayesteh received her MSc in Microbiology from the University of Vienna, Austria and an MBA from the Open University Business School, Milton Keynes, UK.
SFL Regulatory Affairs & Scientific Communication Ltd.